Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01033409 · ClinicalTrials.gov registry record · Phase 1
Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA
A Phase 1 study, sponsored by Arizona State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01033409 is a Phase 1 study that has completed, run by Arizona State University. The registered enrollment target is 60 participants.
The verdict
NCT01033409, a Phase 1 study, has completed, sponsored by Arizona State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe and tolerable, single, oral dose levels in adult subjects.
Interventions
- BIOLOGICAL Salmonella Typhi-vectored pneumonia vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01033409
The ClinicalTrials.gov registry entry for NCT01033409 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arizona State University, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Salmonella Typhi-vectored pneumonia vaccine is the first listed.
NCT01033409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01033409 about?
NCT01033409 is a clinical study titled "Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA". In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe and tolerable, single, oral dose levels in adult subjects.
What is the current status of trial NCT01033409?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2009-08. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01033409?
The interventions under investigation include: Salmonella Typhi-vectored pneumonia vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01033409?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.